Alnylam to Webcast Presentations at Upcoming May Investor Conferences
April 26 2016 - 4:00PM
Business Wire
Alnylam Pharmaceuticals, Inc.
(Nasdaq: ALNY), the leading RNAi therapeutics company, announced
today that management will present company overviews at the
Deutsche Bank 41st Annual Health Care Conference on Wednesday, May
4, 2016 at 8:40 am ET at the InterContinental Hotel in Boston,
Massachusetts, and at the Bank of America Merrill Lynch 2016 Health
Care Conference on Thursday, May 12, 2016 at 10:00 am PT (1:00 pm
ET) at the Encore at Wynn Las Vegas in Las Vegas, Nevada.
A live audio webcast of each presentation will be available on
the Investors section of the company’s website, www.alnylam.com. A
replay will be available on the Alnylam website within 48 hours
after each event.
About Alnylam PharmaceuticalsAlnylam is a
biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is leading the translation
of RNAi as a new class of innovative medicines. Alnylam’s pipeline
of investigational RNAi therapeutics is focused in 3 Strategic
Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline
of RNAi therapeutics for the treatment of rare diseases;
Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics
toward genetically validated, liver-expressed disease targets for
unmet needs in cardiovascular and metabolic diseases; and Hepatic
Infectious Disease, with a pipeline of RNAi therapeutics that
address the major global health challenges of hepatic infectious
diseases. In early 2015, Alnylam launched its “Alnylam 2020”
guidance for the advancement and commercialization of RNAi
therapeutics as a whole new class of innovative medicines.
Specifically, by the end of 2020, Alnylam expects to achieve a
company profile with 3 marketed products, 10 RNAi therapeutic
clinical programs – including 4 in late stages of development –
across its 3 STArs. The company’s demonstrated commitment to RNAi
therapeutics has enabled it to form major alliances with leading
companies including Merck, Medtronic, Novartis, Biogen, Roche,
Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascletis,
Monsanto, The Medicines Company, and Sanofi Genzyme. In addition,
Alnylam holds an equity position in Regulus Therapeutics Inc., a
company focused on discovery, development, and commercialization of
microRNA therapeutics. Alnylam scientists and collaborators have
published their research on RNAi therapeutics in over 200
peer-reviewed papers, including many in the world’s top scientific
journals such as Nature, Nature Medicine, Nature Biotechnology,
Cell, New England Journal of Medicine, and The Lancet. Founded in
2002, Alnylam maintains headquarters in Cambridge, Massachusetts.
For more information about Alnylam’s pipeline of investigational
RNAi therapeutics, please visit www.alnylam.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160426005019/en/
Alnylam Pharmaceuticals, Inc.Investors and MediaChristine Regan
Lindenboom, 617-682-4340orInvestorsJosh Brodsky, 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024